Primary orbital mesenchymal chondrosarcoma: clinicopathological characteristics and prognostic prediction.

IF 3.3 4区医学 Q1 OPHTHALMOLOGY

Canadian journal of ophthalmology. Journal canadien d'ophtalmologie Pub Date : 2024-11-07 DOI:10.1016/j.jcjo.2024.10.013

Te Zhang, Huijing Ye, Wei Xiao, Huasheng Yang

{"title":"Primary orbital mesenchymal chondrosarcoma: clinicopathological characteristics and prognostic prediction.","authors":"Te Zhang, Huijing Ye, Wei Xiao, Huasheng Yang","doi":"10.1016/j.jcjo.2024.10.013","DOIUrl":null,"url":null,"abstract":"Objective: This study aimed to analyze the clinicopathological characteristics of a rare malignant tumour, primary orbital mesenchymal chondrosarcoma (MCS), and identify the risk factors influencing its prognosis.Methods: A total of 15 patients with histologically confirmed primary orbital MCS were enrolled between April 2013 and October 2022. The relationships between clinicopathological features and outcomes, including recurrence and survival were analyzed.Results: During the follow-up period, 9 patients (60%) experienced disease relapse, and 7 patients (46.7%) succumbed to the disease. Immunohistochemical analysis showed positive rates for SMA, CD-99, S-100, vimentin, and Bcl-2 at 60%, 60%, 53.3%, 100%, and 93.3%, respectively. The Ki67 index was positively associated with the recurrence and mortality rates.Conclusion: Our study suggested that the Ki67 index could be a vital prognostic factor for MCS. Further follow-up studies are required to assess the efficacy of chemotherapy and radiotherapy in improving patient outcomes.","PeriodicalId":9606,"journal":{"name":"Canadian journal of ophthalmology. Journal canadien d'ophtalmologie","volume":" ","pages":""},"PeriodicalIF":3.3000,"publicationDate":"2024-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Canadian journal of ophthalmology. Journal canadien d'ophtalmologie","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.jcjo.2024.10.013","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: This study aimed to analyze the clinicopathological characteristics of a rare malignant tumour, primary orbital mesenchymal chondrosarcoma (MCS), and identify the risk factors influencing its prognosis.

Methods: A total of 15 patients with histologically confirmed primary orbital MCS were enrolled between April 2013 and October 2022. The relationships between clinicopathological features and outcomes, including recurrence and survival were analyzed.

Results: During the follow-up period, 9 patients (60%) experienced disease relapse, and 7 patients (46.7%) succumbed to the disease. Immunohistochemical analysis showed positive rates for SMA, CD-99, S-100, vimentin, and Bcl-2 at 60%, 60%, 53.3%, 100%, and 93.3%, respectively. The Ki67 index was positively associated with the recurrence and mortality rates.

Conclusion: Our study suggested that the Ki67 index could be a vital prognostic factor for MCS. Further follow-up studies are required to assess the efficacy of chemotherapy and radiotherapy in improving patient outcomes.

查看原文本刊更多论文

原发性眼眶间质软骨肉瘤：临床病理特征和预后预测。

目的：本研究旨在分析一种罕见恶性肿瘤--原发性眼眶间质软骨肉瘤（MCS）的临床病理特征，并确定影响其预后的风险因素：方法：2013年4月至2022年10月期间，共纳入15例经组织学确诊的原发性眼眶间质软骨肉瘤患者。分析了临床病理特征与复发和生存率等预后之间的关系：随访期间，9名患者（60%）复发，7名患者（46.7%）死亡。免疫组化分析显示，SMA、CD-99、S-100、波形蛋白和 Bcl-2 的阳性率分别为 60%、60%、53.3%、100% 和 93.3%。Ki67指数与复发率和死亡率呈正相关：我们的研究表明，Ki67指数可能是MCS的一个重要预后因素。结论：我们的研究表明，Ki67指数可能是MCS的重要预后因素，需要进一步的随访研究来评估化疗和放疗在改善患者预后方面的疗效。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Canadian journal of ophthalmology. Journal canadien d'ophtalmologie 医学-眼科学

CiteScore

3.20

自引率

4.80%

发文量

223

审稿时长

38 days

期刊介绍： Official journal of the Canadian Ophthalmological Society. The Canadian Journal of Ophthalmology (CJO) is the official journal of the Canadian Ophthalmological Society and is committed to timely publication of original, peer-reviewed ophthalmology and vision science articles.